Introduction
— RCC is categorized by histologic subtype, with clear cell RCC (ccRCC) comprising approximately 70% of tumors, and the remaining histologic subtypes, including papillary and chromophobe RCC, grouped together and classified as non-clear cell RCC (nccRCC).

Methods
— 1468P - IO-Synthesise RCC: Real-world outcomes of nivolumab in patients with previously treated advanced non-clear cell RCC (nccRCC): a pooled analysis from France and Germany

Results
— The median overall survival (OS) was 8.1 (95% CI 5.2-20.9) months with an estimated survival probability of 48% (95% CI 34-62) and 35% (95% CI 24-49) at 24 months (Figure 2).
— Of the 6 patients who had a sarcomatoid component, 1 patient had PR, 2 had SD, and 3 experienced PD; no patient had CR (Table 2).

Conclusions
— 1468P - IO-Synthesise RCC: Real-world outcomes of nivolumab in patients with previously treated advanced non-clear cell RCC (nccRCC): a pooled analysis from France and Germany

Safety
— No TRAE leading to death was reported

References
— 1468P - IO-Synthesise RCC: Real-world outcomes of nivolumab in patients with previously treated advanced non-clear cell RCC (nccRCC): a pooled analysis from France and Germany

Acknowledgments
— No competing interests were declared

Disclosures
— No competing interests were declared

Here is the plain text representation of the document:

**Introduction**

— RCC is categorized by histologic subtype, with clear cell RCC (ccRCC) comprising approximately 70% of tumors, and the remaining histologic subtypes, including papillary and chromophobe RCC, grouped together and classified as non-clear cell RCC (nccRCC).

**Methods**

— 1468P - IO-Synthesise RCC: Real-world outcomes of nivolumab in patients with previously treated advanced non-clear cell RCC (nccRCC): a pooled analysis from France and Germany

**Results**

— The median overall survival (OS) was 8.1 (95% CI 5.2-20.9) months with an estimated survival probability of 48% (95% CI 34-62) and 35% (95% CI 24-49) at 24 months (Figure 2).
— Of the 6 patients who had a sarcomatoid component, 1 patient had PR, 2 had SD, and 3 experienced PD; no patient had CR (Table 2).

**Conclusions**

— 1468P - IO-Synthesise RCC: Real-world outcomes of nivolumab in patients with previously treated advanced non-clear cell RCC (nccRCC): a pooled analysis from France and Germany

**Safety**

— No TRAE leading to death was reported

**References**

— 1468P - IO-Synthesise RCC: Real-world outcomes of nivolumab in patients with previously treated advanced non-clear cell RCC (nccRCC): a pooled analysis from France and Germany

**Acknowledgments**

— No competing interests were declared

**Disclosures**

— No competing interests were declared